This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Revance Therapeutics’s 8K filing here.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
Further Reading
- Five stocks we like better than Revance Therapeutics
- What is a Stock Market Index and How Do You Use Them?
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
- Consumer Discretionary Stocks Explained
- Zeta Global Holdings Insiders Buy Stock After Short-Report
- How to Invest in the FAANG Stocks
- 3 Stocks That Never Lived Up to the Hype
